Share this article on:


Advances in Skin & Wound Care: March 2014 - Volume 27 - Issue 3 - p 106
doi: 10.1097/01.ASW.0000444644.34123.12
INFOLINK: Industry News

Organogenesis Inc, Canton, Massachusetts, has purchased the Dermagraft assets (human fibroblast-derived dermal substitute) from Shire, Dublin Ireland. Dermagraft is approved for the treatment of nonhealing diabetic foot ulcers in the United States and Canada. Organogenesis will continue to manufacture and distribute Dermagraft from its existing facilities in La Jolla, California.


Derma Sciences, Princeton, New Jersey, announced it has licensed exclusive rights to 2 novel human placental-derived tissue products for all dermal indications in the advanced wound care and burn markets from BioD LLC, a privately held company based in Memphis, Tennessee. These products will be branded as AmnioMatrix and launched during the third quarter of 2014.


© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins. All world rights reserved.